title: Acute skin reaction suggestive of pembrolizumab-induced radiosensitization.
abstract: The combination of localized radiotherapy and immune checkpoint inhibitors represents a promising therapeutic strategy for various cancers, including metastatic melanoma. Radiation therapy may enhance tumor antigen presentation and cytokine release, which may optimize the systemic antitumor immune response induced by these immunotherapeutic antibodies, with a potential delayed abscopal effect. However, clinical experience of using immune checkpoint inhibitors with concurrent radiotherapy remains scarce. We report here for the first time a case suggestive of acute skin radiosensitization induced by pembrolizumab, with a suggestive time relationship between the completion of ionizing radiation, drug administration, and rapid onset of the skin reaction. This suggests that radiation therapy may also interact rapidly with anti-programmed-death 1 antibodies. Therefore, caution should be exercised when prescribing this combination therapy in advanced cancers.
authors: Departments of aDermatology bRadiation Oncology cPathology dClinical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France.
authors: Vincent
authors: V
authors: Sibaud
authors: Isabelle
authors: I
authors: David
authors: Laurence
authors: L
authors: Lamant
authors: Sarah
authors: S
authors: Resseguier
authors: Roxana
authors: R
authors: Radut
authors: Justine
authors: J
authors: Attal
authors: Nicolas
authors: N
authors: Meyer
authors: Jean-Pierre
authors: JP
authors: Delord
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary; D059248:Chemoradiotherapy / Q000009:adverse effects* / Q000379:methods; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000532:radiotherapy*; D011855:Radiodermatitis / Q000188:drug therapy / Q000473:pathology*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*
chemical_list: D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C582435:pembrolizumab